NO982794L - Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser - Google Patents

Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser

Info

Publication number
NO982794L
NO982794L NO982794A NO982794A NO982794L NO 982794 L NO982794 L NO 982794L NO 982794 A NO982794 A NO 982794A NO 982794 A NO982794 A NO 982794A NO 982794 L NO982794 L NO 982794L
Authority
NO
Norway
Prior art keywords
aur
polypeptides
diagnosis
treatment
related disorders
Prior art date
Application number
NO982794A
Other languages
English (en)
Other versions
NO982794D0 (no
NO323646B1 (no
Inventor
Gregory D Plowman
Kevin G Moissie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982794(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of NO982794D0 publication Critical patent/NO982794D0/no
Publication of NO982794L publication Critical patent/NO982794L/no
Publication of NO323646B1 publication Critical patent/NO323646B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO19982794A 1995-12-18 1998-06-17 Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate. NO323646B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14
PCT/US1996/018859 WO1997022702A1 (en) 1995-12-18 1996-11-25 Diagnosis and treatment of aur-1 and/or aur-2 related disorders

Publications (3)

Publication Number Publication Date
NO982794D0 NO982794D0 (no) 1998-06-17
NO982794L true NO982794L (no) 1998-08-18
NO323646B1 NO323646B1 (no) 2007-06-18

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982794A NO323646B1 (no) 1995-12-18 1998-06-17 Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate.

Country Status (15)

Country Link
US (2) US5962312A (no)
EP (2) EP1655369A1 (no)
JP (1) JP3944241B2 (no)
KR (1) KR100459052B1 (no)
AT (1) ATE315654T1 (no)
AU (1) AU716330B2 (no)
CA (1) CA2239692C (no)
DE (1) DE69635740T2 (no)
DK (1) DK0868519T3 (no)
ES (1) ES2255715T3 (no)
IL (1) IL124728A (no)
NO (1) NO323646B1 (no)
NZ (1) NZ323795A (no)
PT (1) PT868519E (no)
WO (1) WO1997022702A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6759212B1 (en) * 1997-08-15 2004-07-06 Chugai Seiyaku Kabushiki Kaisha Cell cycle-regulating proteins
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
US6872533B2 (en) 2001-07-27 2005-03-29 The Regents Of The University Of California STK15 (STK6) gene polymorphism and methods of determining cancer risk
AU2003215460A1 (en) * 2002-03-28 2003-10-13 Qlt Inc. Cancer associated protein kinases and their uses
FR2840905B1 (fr) * 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
DE60335636D1 (de) * 2002-09-11 2011-02-17 Genentech Inc Zusammensetzungen und verfahren für die tumordiagnose und behandlung
JP4606879B2 (ja) * 2002-11-15 2011-01-05 ジェノミック ヘルス, インコーポレイテッド Egfr陽性癌の遺伝子発現プロファイリング
DK1847539T3 (da) 2002-12-24 2009-11-09 Astrazeneca Ab Quinazolin-derivater
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
ATE412779T1 (de) * 2003-02-20 2008-11-15 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
CA2531967C (en) * 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050095634A1 (en) * 2003-10-16 2005-05-05 Genomic Health Inc. qRT-PCR assay system for gene expression profiling
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
ATE498022T1 (de) * 2003-12-23 2011-02-15 Genomic Health Inc Universelle vervielfältigung von fragmentierter rns
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006031273A2 (en) * 2004-06-18 2006-03-23 Cytokinetics, Inc. Cellular phenotype
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006052862A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
AU2005304878B2 (en) * 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
WO2006108489A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
US20070082327A1 (en) * 2005-09-09 2007-04-12 Cytokinetics, Inc. A Delaware Corporation Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007079445A2 (en) * 2006-01-03 2007-07-12 Sunesis Pharmaceuticals, Inc. Aurora expression constructs
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Hla−a2拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
CA2157774A1 (en) * 1993-04-07 1994-10-13 Christopher John Marshall Methods for screening of substances for therapeutic activity and yeast for use therein
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
US5972676A (en) 1999-10-26
EP0868519A1 (en) 1998-10-07
DK0868519T3 (da) 2006-05-08
US5962312A (en) 1999-10-05
IL124728A0 (en) 1999-01-26
WO1997022702A1 (en) 1997-06-26
NO982794D0 (no) 1998-06-17
CA2239692C (en) 2008-12-16
AU1082697A (en) 1997-07-14
JP3944241B2 (ja) 2007-07-11
ES2255715T3 (es) 2006-07-01
JP2000502895A (ja) 2000-03-14
CA2239692A1 (en) 1997-06-26
KR20000064437A (ko) 2000-11-06
EP0868519B1 (en) 2006-01-11
KR100459052B1 (ko) 2005-01-15
PT868519E (pt) 2006-05-31
NO323646B1 (no) 2007-06-18
DE69635740T2 (de) 2006-09-14
NZ323795A (en) 2000-01-28
DE69635740D1 (de) 2006-04-06
IL124728A (en) 2007-06-03
AU716330B2 (en) 2000-02-24
ATE315654T1 (de) 2006-02-15
EP1655369A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
NO982794L (no) Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser
WO1999037788A3 (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EP1053245A4 (en) 45 HUMAN SECRETED PROTEINS
DE69117949D1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE69841607D1 (de) Menschliche Toll-Homologe
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
WO2000017222A8 (en) 31 human secreted proteins
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
DE3751893D1 (de) Polypeptid und dessen Herstellung
ATE265533T1 (de) Saeugetierchemokine
WO1996037610A3 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs
EP1333092A3 (en) 28 human secreted proteins
EP1394252A3 (en) 70 human secreted proteins
EP1428833A3 (en) 207 human secreted proteins
EP1346999A3 (en) Human secreted protein
EP1557426A9 (en) 45 human secreted proteins

Legal Events

Date Code Title Description
MK1K Patent expired